ProMetic Life Sciences Inc. (TSE:PLI) Director Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of C$1.45, for a total value of C$60,069.15.
ProMetic Life Sciences Inc. (PLI) traded up 0.68% during trading on Tuesday, hitting $1.47. The stock had a trading volume of 407,146 shares. The stock has a 50 day moving average price of $1.44 and a 200-day moving average price of $1.89. ProMetic Life Sciences Inc. has a 12 month low of $1.12 and a 12 month high of $3.24. The stock’s market cap is $1.04 billion.
TRADEMARK VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/09/12/insider-selling-prometic-life-sciences-inc-pli-director-sells-41427-shares-of-stock.html.
Several research firms have recently issued reports on PLI. Royal Bank Of Canada reissued an “outperform” rating on shares of ProMetic Life Sciences in a research note on Wednesday, May 24th. Canaccord Genuity reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research note on Monday, June 19th. Scotiabank reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research note on Friday, July 7th. National Bank Financial boosted their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a research note on Wednesday, August 30th. Finally, TD Securities reduced their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research note on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. ProMetic Life Sciences has an average rating of “Buy” and a consensus target price of C$3.60.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.